{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:56:06Z","timestamp":1793044566895,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jconrel.2020.10.032","type":"journal-article","created":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T11:02:39Z","timestamp":1602932559000},"page":"1037-1045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Alpha-dystroglycan binding peptide A2G80-modified stealth liposomes as a muscle-targeting carrier for Duchenne muscular dystrophy"],"prefix":"10.1016","volume":"329","author":[{"given":"Eri","family":"Sasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanae","family":"Sashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhito","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Nirasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Katagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamato","family":"Kikkawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichi","family":"Hirashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Endo-Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyoshi","family":"Nomizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Negishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2020.10.032_bb0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-U","article-title":"Population frequencies of inherited neuromuscular diseases-A world survey","volume":"1","author":"Emery","year":"1991","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0010","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2020.10.032_bb0015","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/jpm3030144","article-title":"Antisense therapy in neurology","volume":"3","author":"Lee","year":"2013","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0020","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1440-1789.2009.01028.x","article-title":"Exon-skipping therapy for Duchenne muscular dystrophy","volume":"29","author":"Nakamura","year":"2009","journal-title":"Neuropathology"},{"key":"10.1016\/j.jconrel.2020.10.032_bb0025","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1126\/science.aad5725","article-title":"Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy","volume":"351","author":"Long","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2020.10.032_bb0030","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0035","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/bc070060v","article-title":"Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide \u2013 morpholino oligomer conjugate","volume":"18","author":"Amantana","year":"2007","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0040","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.toxrep.2015.05.008","article-title":"The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse","volume":"2","author":"Zhang","year":"2015","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0045","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.omtn.2019.01.008","article-title":"Scavenger receptor class A1 mediates uptake of morpholino antisense oligonucleotide into dystrophic skeletal muscle","volume":"14","author":"Miyatake","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2020.10.032_bb0050","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/gt.2009.59","article-title":"A muscle-targeting peptide displayed on AAV2 improves muscle tropism on systemic delivery","volume":"16","author":"Yu","year":"2009","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/genes8020065","article-title":"Advances in non-viral DNA vectors for gene therapy","volume":"8","author":"Hardee","year":"2017","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.jconrel.2020.10.032_bb0060","doi-asserted-by":"crossref","first-page":"51","DOI":"10.18609\/cgti.2019.007","article-title":"Non-viral vector mediated gene delivery: the outsider to watch out for in gene therapy","volume":"5","author":"Nyamay\u2019Antu","year":"2019","journal-title":"Cell Gene Ther. Insights"},{"key":"10.1016\/j.jconrel.2020.10.032_bb0065","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.matbio.2009.09.006","article-title":"Identification of \u03b1-dystroglycan binding sequences in the laminin \u03b12 chain LG4\u20135 module","volume":"29","author":"Suzuki","year":"2010","journal-title":"Matrix Biol."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0070","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pharmthera.2019.05.017","article-title":"Laminin-derived peptides: applications in drug delivery systems for targeting","volume":"202","author":"Negishi","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0075","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T","article-title":"Molecular basis of muscular dystrophies","volume":"23","author":"Cohn","year":"2000","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jconrel.2020.10.032_bb0080","doi-asserted-by":"crossref","first-page":"20583","DOI":"10.1074\/jbc.270.35.20583","article-title":"Identification of cell binding sites in the laminin \u03b11 chain carboxyl- terminal globular domain by systematic screening of synthetic peptides","volume":"270","author":"Nomizu","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0085","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2012.28","article-title":"Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA","volume":"1","author":"Belliveau","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2020.10.032_bb0090","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1023\/A:1014434732752","article-title":"Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity","volume":"19","author":"Moreira","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0095","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1248\/bpb.b18-00151","article-title":"Development of a screening system for targeting carriers using peptide-modified liposomes and tissue sections","volume":"41","author":"Negishi","year":"2018","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0100","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0105","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae \u2013 the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.10.032_bb0115","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0378-5173(02)00075-3","article-title":"Effects of mixed polyethyleneglycol modification on fixed aqueous layer thickness and antitumor activity of doxorubicin containing liposome","volume":"238","author":"Sadzuka","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0120","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.15252\/emmm.201403967","article-title":"Inflammatory monocytes promote progression of Duchenne muscular dystrophy and can be therapeutically targeted via CCR2","volume":"6","author":"Mojumdar","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0125","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.2147\/DDDT.S110163","article-title":"Anti-inflammatory drugs for duchenne muscular dystrophy: focus on skeletal muscle-releasing factors","volume":"10","author":"Miyatake","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.0021-8782.2001.00008.x","article-title":"Evans Blue Dye as an in vivo marker of myofibre damage: optimising parameters for detecting initial myofibre membrane permeability","volume":"200","author":"Hamer","year":"2002","journal-title":"J. Anat."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0135","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/jb\/118.5.959","article-title":"Visualization of dystrophic muscle fibers in mdx mouse by vital staining with evans blue: evidence of apoptosis in dystrophin-deficient muscle","volume":"118","author":"Matsuda","year":"1995","journal-title":"J. Biochem."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0140","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/1097-4598(200009)23:9<1344::AID-MUS4>3.0.CO;2-F","article-title":"A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy","volume":"23","author":"Bonifati","year":"2000","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jconrel.2020.10.032_bb0145","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00439-013-1302-7","article-title":"Mouse models of fukutin-related protein mutations show a wide range of disease phenotypes","volume":"132","author":"Blaeser","year":"2013","journal-title":"Hum. Genet."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0150","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/mus.25378","article-title":"Expression of glycosylated \u03b1-dystroglycan in newborn skeletal and cardiac muscles of fukutin related protein (FKRP) mutant mice","volume":"55","author":"Keramaris","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jconrel.2020.10.032_bb0155","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123855","article-title":"Stabilization of the cardiac sarcolemma by sarcospan rescues DMD-associated cardiomyopathy","author":"Parvatiyar","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jconrel.2020.10.032_bb0160","doi-asserted-by":"crossref","first-page":"134833","DOI":"10.1016\/j.neulet.2020.134833","article-title":"The role of the dystrophin glycoprotein complex on the neuromuscular system","volume":"722","author":"Belhasan","year":"2020","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0165","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3233\/JND-160194","article-title":"Cardiac involvement classification and therapeutic management in patients with Duchenne muscular dystrophy","volume":"4","author":"Fayssoil","year":"2017","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms1306","article-title":"Chemical treatment enhances skipping of a mutated exon in the dystrophin gene","volume":"2","author":"Nishida","year":"2011","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0175","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2020.10.032_bb0180","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/0091270006297140","article-title":"Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers","volume":"47","author":"Hirawat","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0185","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1093\/hmg\/ddz044","article-title":"Sunitinib promotes myogenic regeneration and mitigates disease progression in the mdx mouse model of Duchenne muscular dystrophy","volume":"28","author":"Fontelonga","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-17029-3","article-title":"Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing","volume":"11","author":"Wei","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0195","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1074\/jbc.M007540200","article-title":"Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery","volume":"276","author":"Futaki","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0200","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.bbamem.2006.04.015","article-title":"Cellular uptake and subsequent intracellular trafficking of R8-liposomes introduced at low temperature","volume":"1758","author":"Iwasa","year":"2006","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0205","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/10717544.2016.1253121","article-title":"PCM and TAT co-modified liposome with improved myocardium delivery: in vitro and in vivo evaluations","volume":"24","author":"Wang","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0210","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijpharm.2015.02.063","article-title":"Microfluidic-controlled manufacture of liposomes for the solubilisation of a poorly water soluble drug","volume":"485","author":"Kastner","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0215","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ijpharm.2016.09.027","article-title":"Microfluidics based manufacture of liposomes simultaneously entrapping hydrophilic and lipophilic drugs","volume":"514","author":"Joshi","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0220","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1021\/acs.molpharmaceut.9b00583","article-title":"Robust microfluidic technology and new lipid composition for fabrication of curcumin-loaded liposomes: effect on the anticancer activity and safety of cisplatin","volume":"16","author":"Hamano","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2020.10.032_bb0225","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1021\/acs.accounts.9b00368","article-title":"Lipid nanoparticle technology for clinical translation of siRNA therapeutics","volume":"52","author":"Kulkarni","year":"2019","journal-title":"Acc. Chem. Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920306106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920306106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:13:53Z","timestamp":1759162433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365920306106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":45,"alternative-id":["S0168365920306106"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.10.032","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alpha-dystroglycan binding peptide A2G80-modified stealth liposomes as a muscle-targeting carrier for Duchenne muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.10.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}